急性髓系白血病的缓解诱导。
Remission induction in acute myeloid leukemia.
机构信息
Memorial Sloan Kettering Cancer Center, Leukemia Service, New York, NY 10065, USA.
出版信息
Int J Hematol. 2012 Aug;96(2):164-70. doi: 10.1007/s12185-012-1121-y. Epub 2012 Jul 13.
Abstract
Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 + 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome.
摘要
在急性髓系白血病患者中诱导完全缓解（CR）是长期疾病控制的前提，随后进行缓解后巩固化疗或异基因造血干细胞移植。基于 20 世纪 80 年代进行的临床试验，使用 7 天输注阿糖胞苷和 3 天柔红霉素或伊达比星（7+3）已成为诱导 CR 的标准治疗方法。尽管人们努力提高 7+3 方案的 CR 率，从而提高整体患者生存率，但结果令人失望。在这里，我们回顾了最近的 III 期新型诱导策略研究，这些研究显示出提高 CR 率和改善疾病结局的潜力。
相似文献
1
Remission induction in acute myeloid leukemia.
Int J Hematol. 2012 Aug;96(2):164-70. doi: 10.1007/s12185-012-1121-y. Epub 2012 Jul 13.
2
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
3
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
J Clin Oncol. 2013 Mar 1;31(7):923-9. doi: 10.1200/JCO.2012.45.2177. Epub 2012 Nov 5.
4
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.
Hematol Oncol. 2015 Dec;33(4):212-9. doi: 10.1002/hon.2173. Epub 2014 Nov 3.
5
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Leukemia. 1999 Jun;13(6):843-9. doi: 10.1038/sj.leu.2401445.
6
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
N Engl J Med. 1995 Jan 26;332(4):217-23. doi: 10.1056/NEJM199501263320403.
7
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Ter Arkh. 2018 Aug 17;90(7):14-22. doi: 10.26442/terarkh201890714-22.
8
9
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Ann Hematol. 2020 Apr;99(4):773-780. doi: 10.1007/s00277-020-03922-w. Epub 2020 Feb 22.
10
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Haematologica. 2007 Mar;92(3):389-96. doi: 10.3324/haematol.10552.
引用本文的文献
1
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Ann Hematol. 2024 Apr;103(4):1187-1196. doi: 10.1007/s00277-024-05639-6. Epub 2024 Jan 30.
2
The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation.
Front Immunol. 2022 Jul 7;13:932228. doi: 10.3389/fimmu.2022.932228. eCollection 2022.
3
Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication.
Cancer Drug Resist. 2022 May 5;5(2):344-367. doi: 10.20517/cdr.2021.140. eCollection 2022.
4
Influence of Dose Intensity in Consolidation with HIDAC and Other Clinical and Biological Parameters in the Survival of AML.
J Cancer Epidemiol. 2020 Jun 24;2020:8021095. doi: 10.1155/2020/8021095. eCollection 2020.
5
Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia.
Blood Adv. 2020 Jan 28;4(2):387-397. doi: 10.1182/bloodadvances.2019000715.
6
Drug Shortage Impacts Patient Receipt of Induction Treatment.
Health Serv Res. 2018 Dec;53(6):5078-5105. doi: 10.1111/1475-6773.13028. Epub 2018 Sep 10.
7
High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.
PLoS One. 2016 Apr 13;11(4):e0153207. doi: 10.1371/journal.pone.0153207. eCollection 2016.
8
A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions.
Case Rep Hematol. 2014;2014:141260. doi: 10.1155/2014/141260. Epub 2014 Oct 2.
9
The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.
J Immunol. 2014 Sep 15;193(6):2994-3002. doi: 10.4049/jimmunol.1302600. Epub 2014 Aug 13.
10
Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.
Haematologica. 2014 Aug;99(8):1277-84. doi: 10.3324/haematol.2013.085209.
本文引用的文献
1
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
J Clin Oncol. 2012 Jul 10;30(20):2441-8. doi: 10.1200/JCO.2011.37.1286. Epub 2012 Apr 16.
2
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5.
3
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14.
4
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
Blood. 2011 Oct 6;118(14):3832-41. doi: 10.1182/blood-2011-06-361410. Epub 2011 Aug 9.
5
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20.
6
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6.
7
Anthracycline dose intensification in acute myeloid leukemia.
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.
8
High-dose daunorubicin in older patients with acute myeloid leukemia.
N Engl J Med. 2009 Sep 24;361(13):1235-48. doi: 10.1056/NEJMoa0901409.
9
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
Blood. 1982 Aug;60(2):454-62.
10
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
Blood. 1981 Dec;58(6):1203-12.
Zotero 插件